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Regulation of protein phosphatase 1 (PP1) by protein inhibitors
and targeting subunits has been previously studied through the
use of recombinant protein expressed in Escherichia coli. This
preparation is limited by several key differences in its properties
compared with native PP1. In the present study, we have analyzed
recombinant PP1 expressed in Sf9 insect cells using baculovirus. Sf9
PP1 exhibited properties identical to those of native PP1, with
respect to regulation by metals, inhibitor proteins, and targeting
subunits, and failure to dephosphorylate a phosphotyrosine-con-
taining substrate or phospho-DARPP-32 (Dopamine and cAMP-
regulated phosphoprotein, Mr 32,000). Mutations at Y272 in the
b12yb13 loop resulted in a loss of activity and reduced the sensi-
tivity to thiophospho-DARPP-32 and inhibitor-2. Mutations of Y272
also increased the relative activity toward a phosphotyrosine-
containing substrate or phospho-DARPP-32. Mutation of acidic
groove residues caused no change in sensitivity to thiophospho-
DARPP-32 or inhibitor-2, but one mutant (E252A:D253A:E256R)
exhibited an increased Km for phosphorylase a. Several PP1yPP2A
chimeras were prepared in which C-terminal sequences of PP2A
were substituted into PP1. Replacement of residues 274–330 of PP1
with the corresponding region of PP2A resulted in a large loss of
sensitivity to thiophospho-DARPP-32 and inhibitor-2, and also
resulted in a loss of interaction with the targeting subunits,
spinophilin and PP1 nuclear targeting subunit (PNUTS). More lim-
ited alterations in residues in b12, b13, and b14 strands highlighted
a key role for M290 and C291 in the interaction of PP1 with
thiophospho-DARPP-32, but not inhibitor-2.
Protein phosphatase 1 (PP1) is a major eukaryotic serineythreonine protein phosphatase that regulates such diverse
cellular processes as cell cycle progression, protein synthesis,
muscle contraction, carbohydrate metabolism, transcription, and
neuronal signaling (1–4). The catalytic subunit of PP1 is regu-
lated by the heat-stable protein inhibitor-1, its homologue
DARPP-32 (dopamine- and cAMP-regulated phosphoprotein,
Mr 32,000), and inhibitor-2 (1, 5). Phosphorylation of inhibitor-1
at T35 or of DARPP-32 at T34 by cAMP-dependent protein
kinase is required for PP1 inhibition. In contrast, unphosphor-
ylated inhibitor-2 interacts with the PP1 catalytic subunit, lead-
ing first to the inhibition of enzymatic activity and, subsequently,
to the formation of an inactive complex termed Mg-ATP-
dependent phosphatase (6). PP1 also interacts with a variety of
regulatory subunits that target the catalytic subunit to specific
subcellular compartments (4). These include the glycogen-
targeting subunits, GM and GL (7), the myofibrillar-targeting
subunit, M110 (7), the nuclear-targeting proteins, nuclear inhib-
itor of PP1 (NIPP-1) (8) and PP1 nuclear targeting subunit
(PNUTS) (9, 10), and the neuronal dendritic spine-targeting
proteins, spinophilin and neurabin (11, 12).
Numerous studies have shown that PP1 interacts with
DARPP-32yinhibitor-1 and targeting subunits via a common
docking motif that consists of one or more basic amino acids
followed by two hydrophobic residues that are separated by a
variable amino acid (13–17). X-ray crystallographic analysis of
GMyPP1 has indicated that the docking motif (RRVSF) interacts
in an extended manner with a hydrophobic channel in PP1
situated on the side opposite that of the active site (14). Residues
that form the hydrophobic channel come from several b-strands,
including b12, b13, and b14. In addition to the interaction via the
docking motif, DARPP-32yinhibitor-1 (and possibly some of the
targeting proteins) likely make additional contacts with b12,
b13, and b14 such that the phospho-T34yT35 comes close to, or
even occupies, the PP1 active site (5). In contrast, inhibitor-2
does not seem to contain a canonical RRVSF docking motif.
Rather, inhibitor-2 possesses a unique N-terminal motif that
interacts with a region of PP1 that is slightly removed from the
hydrophobic channel discussed above (5, 18).
Several studies indicate that the b12, b13, and b14 strands play
a key role in the highly specific interactions of protein inhibitors
and targeting subunits with PP1 (14, 19–21). Indeed, replace-
ment of the C terminus of PP1, including the b12–b14 strands,
with the corresponding region of the structurally related protein
phosphatase, PP2A, renders the chimeric phosphatase activity
insensitive to inhibitor-1 and inhibitor-2 (22). Surprisingly, the
PP1yPP2A chimera still apparently bound these proteins. To
further analyze PP1 regulation by inhibitors and targeting sub-
units, many studies have used site-directed mutagenesis of the
PP1 catalytic subunit expressed in Escherichia coli (20, 21, 23).
However, E. coli PP1 differs from native PP1 in several impor-
tant properties: it depends on added Mn21 for activity; it is able
to dephosphorylate phospho-tyrosine-containing substrates and
para-nitrophenyl phosphate; it is relatively insensitive to inhibi-
tion by phospho-DARPP-32 and phospho-inhibitor-1, partly
through the dephosphorylation of the phospho-inhibitors (16,
20, 24, 25); and it is insensitive to regulation by several targeting
subunits (unpublished results).
In the present study, we have used a baculovirus expression
system in Sf9 insect cells to produce a recombinant PP1 prep-
aration that exhibited properties very similar to those of native
PP1. We have used this enzyme preparation to carry out detailed
structure–function studies of PP1. The results obtained have
provided insights into the interaction of PP1 with inhibitor
proteins, targeting subunits, and substrates.
Materials and Methods
Materials. Oligonucleotides were synthesized by Operon Tech-
nologies (Alameda, CA). The QuickChange site-directed mu-
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tagenesis kit was from Stratagene. The Bac-to-Bac Baculovirus
Expression System, including the vector plasmid pFastBac-HT,
DH10BAC competent cells, and recombinant tobacco etch virus
(TEV) protease, were from Life Technologies (Rockville, MD).
Sf9 cells were from Novagen. Complete protease inhibitor
mixture tablets and protease inhibitor E-64 were from Roche
Molecular Biochemicals. NHS-Hi Trap and glutathione Sepha-
rose were from Pharmacia Biotech (Uppsala, Sweden). Ni-
nitrilotriacetic acid (Ni-NTA) agarose was from Qiagen (Chats-
worth, CA). Immobilon-P was from Millipore; PNUTS peptide
was synthesized and purified by reversed-phase column HPLC at
W. M. Keck Foundation Biotechnology Resource Laboratory,
Yale University. The Protein Tyrosine Phosphatase Assay Sys-
tem was from New England Biolabs. Monoclonal antibody for
PP1 (E-9) was from Santa Cruz Biotechnology. The catalytic
subunit of native PP1 was purified from rabbit skeletal muscle,
and recombinant PP1 was purified from E. coli as described (20,
26). DARPP-32 and inhibitor-2 were prepared from E. coli as
described (5). GST-tagged spinophilin and GST-PNUTS were
prepared from E. coli as described (9, 27).
Preparation of Baculovirus. Rabbit PP1a cDNA was a generous gift
from N. Berndt (Children’s Hospital of Los Angeles, University
of Southern California School of Medicine, Los Angeles, CA).
EcoRI and XbaI restriction sites were added in the 59end and
39end of the PP1 sequence, and the cDNA was used as a template
for site-directed mutagenesis using PCR. PP1yPP2A chimera
cDNA was amplified by PCR using the CRHM2 plasmid that
encodes residues 1–273 of human PP1a fused in frame with
residues 267–309 of bovine PP2A (22). PCR products were
inserted in frame into pFastBac-HT. For some constructs, cDNA
encoding glutathione S-transferase (GST) followed by a TEV
protease cleavage site, and a FLAG tag was introduced in frame
between the 6xHis tag and PP1 sequences. Thus, proteins had a
6xHis tag, a TEV protease cleavage site, a GST tag, a second
TEV cleavage site, and a FLAG tag at the N terminus of PP1.
The QuickChange kit was used for site-directed mutagenesis.
Recombinant baculovirus stocks were prepared as described
by the manufacturer (Life Technologies). In brief, donor plas-
mids were used for transformation of competent DH10BAC E.
coli cells. Recombinant bacmid DNA was isolated and used for
transfection of Sf9 cells. After 48 h incubation at 28°C, super-
natant from the culture medium was saved and used for further
amplification.
Expression and Purification of Wild-Type and Mutant PP1. Sf9 cells
were grown in suspension culture (28°C, rotating at 135 rpm) in
Grace’s insect medium [supplemented with 0.33% yeastolatey
0.33% lactalbumin hydrolysatey10% (vol/vol) FCS]. Sf9 cells
(1.5 3 106 cells per milliliter) were infected at a multiplicity of
infection between 5–10 plaque-forming units.
For purification of 6xHis-tagged PP1, cells (’2 3 107 per
milliliter) were lysed with buffer containing 0.1 M KCl and 1%
Nonidet P-40. Supernatants (centrifugation at 100,000 3 g for 30
min) were incubated with Ni-NTA agarose and transferred into
a column. The resin was washed with buffer containing 0.5 M
KCl, 10% (volyvol) glycerol, and 20 mM imidazole, and eluted
with buffer containing 0.1 M KCl, 10% (volyvol) glycerol, and
150 mM imidazole. Fractions containing active PP1 were dia-
lyzed against buffer containing 50 mM TriszHCl (pH 7.0), 50%
glycerol, 0.1 mM EGTA, and 0.1% 2-mercaptoethanol. For
purification of GST-tagged PP1, cells (’3 3 107 cells per
milliliter) were lysed with buffer (0.1 M NaCly1% Nonidet
P-40). The supernatant (centrifugation at 100,000 3 g for 30 min)
was incubated with glutathione-Sepharose, and the resin was
pelleted by centrifugation and washed with PBS. The resin was
then resuspended in 50 mM TriszHCl (pH 8.0)y10 mM EDTAy1
mM DTTy10% (vol/vol) glycerol, and incubated with 200 units
of 6xHis-tagged TEV protease. After cleavage, Ni-NTA agarose
was added to the suspension to remove the His-tagged TEV
protease. The suspension was centrifuged, and the supernatant
was used for protein phosphatase assay. For the various PP1
preparations, expression reached a maximum 48–72 h after
infection. Approximately 50% of expressed PP1 was recovered
in the soluble fraction, and ’10 mg of purified protein was
recovered from 1 3 108 cells in 100 ml of culture.
Immunoblotting of Recombinant PP1. Proteins were separated by
SDSyPAGE and electrophoretically transferred to Immobilon-P
membrane by using standard procedures. Membranes were
incubated in PBS containing 0.1% Tween 20, 0.5% nonfat dry
milk, and 1 mgyml anti-PP1 monoclonal antibody (E-9), which
also recognizes the PP1yPP2A chimera and all PP1 mutants.
Rabbit anti-mouse IgG antibody and 125I-labeled protein A were
used for detection of signal. Radioactivity was quantified by
using a PhosphorImager (Molecular Dynamics), and purified
recombinant PP1 of known concentration was used as standard.
Protein Phosphatase Assays. Serineythreonine phosphatase activ-
ity was assayed by using as substrate [32P]phosphorylase a or
[32P]DARPP-32 phosphorylated by cAMP-dependent protein
kinase (26). Assays contained 0.01% (wtyvol) Brij 35, 0.3 mgyml
BSA, 10 mM [32P]phosphorylase a or 1–5 mM [32P]DARPP-32,
various protein inhibitors, and PP1. Assays of E. coli PP1
contained 1 mM MnCl2. For the assay of inhibitors, PP1 and
inhibitors were preincubated for 15 min on ice. For peptide
competition studies, PNUTS (392–408) and protein inhibitors
were mixed before addition of PP1. Phosphorylation and thio-
phosphorylation of DARPP-32 were carried out as described
(20). Tyrosine phosphatase activity was assayed by using as
substrate [32P]myelin basic protein phosphorylated by Abl pro-
tein tyrosine kinase prepared as described by the manufacturer
of the Protein Tyrosine Phosphatase Assay System. All assays
were performed in duplicate, and experiments were repeated at
least two times.
Coprecipitation Assays. GST-tagged PNUTS (residues 309–691)
or GST-tagged spinophilin (residues 298–817) (50 mg) was
incubated with 50 ml of glutathione-Sepharose in 1 ml of binding
buffer (20 mM triethanolamine (pH 7.0)y50 mM NaCly10%
(volyvol) glyceroly0.1% 2-mercaptoethanoly1 mg/ml BSA) at
4°C with rotation. The resin was centrifuged and washed three
times with binding buffer. Protein-bearing resin (20 ml) was
incubated with ’0.2 mM PP1 or PP1yPP2A chimera in 100 ml of
binding buffer containing 0.5 mgyml BSA at 4°C for 2 h. After
three washes with 1 ml of binding buffer, protein coprecipitated
with the beads was eluted by boiling in Laemmli sample buffer
and analyzed by immunoblotting by using anti-PP1 antibody.
Results
Characterization of PP1 Expressed in Sf9 Cells. As discussed above,
E. coli PP1 differs from native PP1 in several ways, limiting the
interpretation of studies carried out with this preparation.
Therefore, we assessed the properties of PP1 expressed in insect
cells using the baculovirus method with that of native rabbit
muscle PP1 and E. coli PP1. Sf9 PP1 exhibited properties
essentially identical to those of native PP1, with respect to its lack
of dependence on added Mn21 (data not shown), its sensitivity
to phospho-DARPP-32 and inhibitor-2 (Fig. 1 and Table 1), its
failure to dephosphorylate tyrosine-phosphorylated myelin basic
protein and phospho-DARPP-32 (Table 2), its ability to bind
tightly to spinophilin and PNUTS, and its ability to be inhibited
by these two targeting subunits (Fig. 2). Thus, Sf9 PP1 is a more
suitable preparation for detailed structure–function analysis.
The C-terminal subdomain of PP1 (that includes b12–b14) sits
on the surface of the N-terminal subdomain, forming three
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surface grooves—the hydrophobic groove, the acidic groove, and
the C-terminal groove—with the active site situated at the
bifurcation point of the three grooves (28, 29). Several residues
in the acidic groove (D220, E252, E256, and E275) are found
only in PP1 (and not in PP2A or PP2B). PP1 preparations in
which these residues were mutated were analyzed with respect to
various enzymatic properties (Tables 1 and 2). Among the acidic
groove mutants, only PP1[E252A:D253A:E256R] exhibited a
significantly higher apparent Km value than wild-type Sf9 PP1 or
native PP1. Mutation of D220, E252, E253, E256, or E275, either
singly or in combination, did not result in any significant change
of sensitivity to thiophospho-DARPP-32 (Table 1).
A loop between b12 and b13 overhangs the active site and
positions a highly conserved residue, Y272, close to the active
site, but its function has remained unclear. Previous studies in
which Y272 was mutated in E. coli PP1 indicated that this residue
plays an important role in the interaction of PP1 with toxins like
okadaic acid, microcystin, and calyculin A, as well as phospho-
DARPP-32, phospho-inhibitor-1, and inhibitor-2 (19–21). Sur-
prisingly, in these previous studies, mutation of Y272 had no
effect on enzyme activity, despite the fact that this residue is
conserved through evolution not only in PP1 but also in PP2A
and PP2B. In contrast, Sf9 PP1[Y272F] exhibited a significant
loss of activity, and Sf9 PP1[Y272A] exhibited a very large loss
of activity, although some activity could be measured at high
substrate concentration (Table 1 and data not shown). However,
consistent with previous results, mutations of Y272 resulted in a
large decrease in sensitivity to thiophospho-DARPP-32 and
inhibitor-2, with a greater effect being observed for PP1[Y272A]
than PP1[Y272F]. The effect of both mutations was greater for
PP1 inhibition by thiophospho-DARPP-32 than that for inhib-
itor-2.
Fig. 1. Inhibition of wild-type Sf9 cell PP1 and PP1yPP2A chimera by thio-
phospho-DARPP-32 and inhibitor-2. Phosphatase activity of wild-type PP1
(closed and open circles) and PP1yPP2A chimera (closed and open squares) was
measured in the absence (closed symbols) or presence (open symbols) of 20 mM
PNUTS[392–408] peptide and the indicated concentrations of thiophospho-
DARPP-32 (A), or inhibitor-2 (B). Phosphatase activity was measured by using
10 mM [32P]phosphorylase a as substrate. Phosphatase activity is expressed as
percent of activity measured in the absence of protein inhibitors.
Table 1. Characterization of wild-type PP1 and PP1 mutants
expressed in Sf9 cells
Km Vmax
S-D32
IC50
I-2
IC50
Wild-type PP1 3.7 18.5 0.7 1.5
D220V 1.6 7.3 0.8 ND
E256R 5.7 6.6 0.8 ND
E275R 3.5 3.9 3.0 ND
E252A:D253A 2.0 3.9 1.8 ND
E252A:D253A:E256R 19.5 2.1 ND ND
Y272F 4.4 0.8 58 4.9
Y272A ND ND 179 54
PP1[GEFD . YRCG] 5.6 0.2 2.3 155
PP1[MC . KY] 1.6 6.4 58 78
PP1[QILK . LQFD] 6.1 1.9 0.7 23
PP1yPP2A Ch 1.8 1.0 400 1,583
PP1yPP2A Ch[YRCG . GEFD] 6.2 4.3 857 345
PP1yPP2A Ch[KY . MC] 1.4 1.8 5.9 1,000
PP1yPP2A Ch[LOFD . QILK] 1.1 0.7 675 2,050
[32P]phosphorylase a was used as substrate. Apparent Km (mM) and Vmax
(mmolymgymin) are given. The IC50 values for thiophospho-DARPP-32 (S-D32)
and inhibitor-2 (I-2) are in nM. ND, not determined. Both thiophospho-
DARPP-32 and inhibitor-2 inhibit native rabbit muscle PP1 with IC50 values of
’1 nM (5). Results are the average of two to six separate experiments.
Table 2. Relative activity of PP1 preparations towards
tyrosine-phosphorylated myelin basic protein and
phospho-DARPP-32
Strain
Phospho-tyr
Myelin basic protein Phospho-D32
Wild-type PP1 (E. coli) 100 100
Native PP1 (rabbit muscle) 0.5 0.5
Wild-type PP1 (Sf9) 2.4 0.8
PP1-Y272F (Sf9) 15.8 6.7
PP1-Y272A (Sf9) 900 150
PP1yPP2A Ch (Sf9) 1.8 2.3
Wild-type PP1 or PP1 mutants were expressed in E. coli or Sf9 cells as
indicated. Native PP1 was purified from rabbit muscle. Phosphatase activity
determined for either substrate was normalized to that determined using
phosphorylase a as standard substrate. The relative phosphatase activities
were then expressed as a percentage of that of wild-type PP1 expressed in E.
coli. Results are the average of three separate experiments.
Fig. 2. Regulation of Sf9 cell PP1 and PP1yPP2A chimera by targeting
subunits. (A) Coprecipitation of PP1 and PP1yPP2A chimera with GST-PNUTS
and GST-spinophilin. Wild-type PP1 (lanes 1, 3, 5, and 7) or PP1yPP2A chimera
(lanes 2, 4, 6, and 8) was incubated with control beads or beads bearing
GST-PNUTS[309–961] (lanes 5 and 6), or GST-spinophilin[298–817] (lanes 7
and 8). After washing, bound PP1 or PP1yPP2A chimera was detected by
immunoblotting. The loaded wild-type PP1 and PP1yPP2A chimera are shown
in lanes 1 and 2 and indicated by arrowheads. The molecular weight of
PP1yPP2A is less than that of PP1 because of its shorter C-terminal tail.
Nonspecific binding to the bead matrix was negligible (lanes 3 and 4). (B and
C) Phosphatase activity of wild-type PP1 (closed circles) and PP1yPP2A chimera
(open circles) was measured in the presence of the indicated concentrations of
GST-PNUTS[309–961] (B) or GST-spinophilin[298–817] (C). Phosphatase activ-
ity was measured as described in the Fig. 1 legend.
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A distinct property of E. coli PP1 is its ability to dephosphor-
ylate phospho-DARPP-32 and tyrosine-phosphorylated sub-
strates (20, 25). Notably, Sf9 PP1, like native PP1, did not
dephosphorylate phospho-DARPP-32 or tyrosine-phosphory-
lated myelin basic protein at any substantial rate (Table 2).
However, mutation of Y272 resulted in an increase in the relative
phosphatase activity toward both tyrosine-phosphorylated my-
elin basic protein and phospho-DARPP-32, with a much larger
effect being observed for PP1[Y272A] than for PP1[Y272F].
Regulation of PP1yPP2A Chimeras by Protein Inhibitors and Targeting
Subunits. Whereas the catalytic domains of PP1 and PP2A exhibit
a high level of amino acid identity, there are significant differ-
ences in their C-terminal subdomains. PP1 and PP2A share the
sequence FSAPNYC at the N-terminal half of the b12yb13 loop,
and then their C termini diverge (Fig. 3). A chimeric protein, in
which the PP2A sequence following the FSAPNYC region
replaced the corresponding C terminus of PP1, was expressed in
E. coli and was found, like PP2A, to exhibit markedly reduced
sensitivity to phospho-inhibitor-1 and inhibitor-2 (ref. 22; see
also ref. 30). The PP1yPP2A chimera expressed in Sf9 cells
exhibited a large decrease in sensitivity to thiophospho-
DARPP-32 and inhibitor-2, although both inhibitors were ef-
fective at concentrations of 1 mM and above (Fig. 1 and Table
1). Addition of a short peptide encompassing the docking motif
of PNUTS [PNUTS (392–408)] (Y. G. Kwon, T.W., P.B.A., M.
Kanarsha, P.G., and A.C.N., unpublished results), antagonized
effectively the inhibition of wild-type Sf9 PP1 by either thio-
phospho-DARPP-32 or inhibitor-2, but had no effect on the
inhibition of the Sf9 PP1yPP2A chimera seen at high concen-
trations of the inhibitors. Direct binding studies using GST-
spinophilin (298–817) or PNUTS (309–691) showed that the Sf9
PP1yPP2A chimera did not interact with either protein (Fig.
2A). In addition, the Sf9 PP1yPP2A chimera was not inhibited
by GST-spinophilin (298–817) or GST-PNUTS (309–691) (Fig.
2 B and C). Finally, the Sf9 PP1yPP2A chimera did not dephos-
phorylate phospho-DARPP-32 or tyrosine-phosphorylated my-
elin basic protein (Table 2).
Following the FSAPNYC sequence, three short regions of
PP1—GEFD (residues 274–277), MC (residues 290–291), and
QILK (residues 294–297)—are substituted with the sequences
YRCG, KY, and LQFD, respectively, of PP2A. To further
investigate the specificity of the interaction of protein inhibitors
and targeting subunits with PP1, we replaced each of the three
short regions in PP1 with the corresponding residues from PP2A.
In addition, we replaced the three corresponding regions of the
PP1yPP2A chimera with the residues found normally in PP1.
Replacement of the MC sequence in PP1 with KY from PP2A
resulted in a large increase in the IC50 for thiophospho-
DARPP-32 (Fig. 4A and Table 1). However, replacement of
QILK with LQFD, or of GEFD with YRCG, had no or little
effect, respectively, on inhibition by thiophospho-DARPP-32.
Conversely, replacement of the KY residues in the PP1yPP2A
chimera with the MC residues found in PP1 largely restored the
sensitivity to inhibition by thiophospho-DARPP-32 (Fig. 4B).
The other two reverse mutations, LQFD to QILK or YRCG to
GEFD, in the chimera had no effect. With respect to regulation
by inhibitor-2, a qualitatively different pattern was observed for
these three sets of mutants. Mutation of GEFD, MC, or QILK
to the corresponding PP2A residues all resulted in a large
increase in the IC50 for inhibitor-2 (Fig. 5 and Table 1). More-
over, none of the reverse mutations of the chimera restored
sensitivity to inhibitor-2.
Discussion
Recombinant PP1, expressed in E. coli, has been used by our
laboratory and several other laboratories to characterize the
Fig. 3. Comparison of C-terminal domains of PP1 and PP2A and construction
of PP1yPP2A chimeras. (A) Alignment of amino acid sequences of human PP1a
and bovine PP2A. Conserved amino acids (including homologous substitu-
tions) are boxed, and identical amino acids are indicated with a gray back-
ground. Positions of b-strands of PP1 are indicated by gray boxes above the
alignment. Amino acids altered in the PP1y2A chimeras are underlined in bold.
(B) Construction of PP1yPP2A chimeras. The highly conserved core region of
PP1 (residues 41–273) and the corresponding region of PP2A are indicated by
light gray and dark gray bars, respectively. N- and C-terminal variable regions
of PP1 and PP2A are indicated by white and black bars.
Fig. 4. Comparison of the regulation of PP1 and PP1yPP2A chimeras by
thiophospho-DARPP-32. Phosphatase activity was measured in the presence
of the indicated concentrations of thiophospho-DARPP-32. (A) Inhibition of
wild-type PP1 and C-terminal domain mutants derived from PP1 as indicated.
(B) Inhibition of PP1yPP2A chimera and mutants derived from the chimera as
indicated. Phosphatase activity was measured as described in the Fig. 1 legend.
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structure and regulation of the enzyme (20, 21, 23). However, E.
coli PP1 exhibits enzymological properties that are very different
from native PP1 (16, 20, 24, 25), and therefore, only limited
conclusions have been drawn from those studies. In the present
study, we have found that PP1 expressed in Sf9 insect cells
exhibited properties essentially identical to those of native rabbit
muscle PP1, making Sf9 PP1 a more appropriate preparation to
use in detailed structure–function analyses.
The crystal structures of PP1 and the related phosphatase,
PP2B, indicate that this class of enzymes contains two metal
atoms embedded at the core of a conserved phosphoesterase
motif (28, 29, 31). In the recombinant E. coli PP1 used for
crystallization, Fe21 and Mn21 most likely are the two metals.
Expression and purification of E. coli PP1 requires addition of
Mn21 to the growth media and purification buffers, and the
purified enzyme is variably dependent on added Mn21, most
likely because of the easy exchange of Mn21 from the active site.
Whereas the identity of the two metals in native PP1 remains
unknown [studies of PP2A and PP2B suggest Fe21 and Zn21 are
the likely candidates (31, 32)], the enzyme is fully active in the
absence of added metals. In this regard, Sf9 PP1 was also fully
active in the absence of added metals. This feature of native and
Sf9 PP1 presumably occurs as a result of tighter binding of metals
by these two preparations because of subtle changes in the
geometry of the active-site metal-binding ligands.
Two crystal structures of E. coli PP1 have been determined,
one of which represents an active form of the enzyme, and the
other (in the presence of microcystin) represents an inhibited
enzyme (28, 29). The two structures are essentially superimpos-
able, the only difference being the position of the b12yb13 loop
(22). Thus, the b12yb13 loop seems to be relatively flexible, and
conceivably its incorrect positioning might be responsible for
some of the different properties of E. coli PP1. In particular, the
exact position of Y272 in the b12yb13 loop may be critical for the
enzymatic properties of PP1. Y272 is conserved in PP1 and all
related PPases, and its hydroxyl oxygen is positioned close to one
of the active-site metals, making a hydrogen bond with an
active-site water molecule (28). However, mutation of Y272 in
E. coli PP1 had no effect on enzyme activity, although this
mutation did affect the sensitivity to toxins, phospho-DARPP-
32, and inhibitor-2 (19–21). In contrast, mutation of Y272 in Sf9
PP1 markedly decreased phosphatase activity, particularly when
substituted with alanine. Moreover, whereas activity toward
serine-phosphorylated phosphorylase a was decreased, the rel-
ative activity toward tyrosine-phosphorylated myelin basic pro-
tein was increased. Together these results suggest that the
correct orientation of the hydrophobic phenol ring of Y272,
situated near the active site, may be sufficient to block access of
bulky tyrosine-phosphorylated substrates to the active site of
native and Sf9 PP1 (and related serineythreonine PPases).
Our previous studies of DARPP-32 (and related studies of
inhibitor-1) have indicated that phosphorylation of T34 (or T35)
by cAMP-dependent protein kinase is essential for inhibition of
PP1 (5, 21). It is likely that phospho-T34 is positioned close to
or in the active site of PP1 in a manner in which it cannot be
dephosphorylated, and thus it inhibits enzyme activity. The
correct positioning of phospho-T34 may depend on the inter-
action of the docking motif of DARPP-32 (RKKIQF, residues
6–11) with the hydrophobic channel situated on the side of the
enzyme opposite from that of the active site. Additional contacts
between DARPP-32 and other parts of the C-terminal subdo-
main of PP1 are also likely. On the basis of initial modeling
studies, we previously suggested that several acidic residues
found in the acidic groove of PP1 might interact with the four
arginine residues that precede phospho-T34 in DARPP-32 (28).
However, mutation of these residues in various combinations in
Sf9 PP1 had no effect on inhibition by thiophospho-DARPP-32.
Subsequent studies have also shown that mutation of R29 and
R30 in DARPP-32 did not affect its inhibitory properties (5).
Together, these studies suggest that it is unlikely that DARPP-32
interacts with the acidic groove of PP1. Paradoxical results in
which mutation of some acidic groove residues in E. coli PP1
actually increased the sensitivity to phospho-DARPP-32 or
phospho-inhibitor-1 (20, 21) presumably reflected nonspecific
changes in active site geometry. It remains possible that the
acidic groove interacts with other PP1-binding proteins or
substrates. Evidence in support of the latter possibility was
obtained from the PP1[E252;D253A:E256R] mutant, which
exhibited an increased apparent Km for phosphorylase a.
In the absence of any interaction with the acidic groove,
alternative modes for the binding of phospho-DARPP-32 or
phospho-inhibitor-1 to PP1 could include their interaction with
the C-terminal groove andyor interaction with the b12yb13 loop.
Previous studies of (presumably) native PP1 using yeast two-
hybrid analysis have indicated that mutations in A268, P269,
A278, and G279 in the b12yb13 loop abrogated PP1 binding and
inhibition by phospho-inhibitor-1 (21). The present study indi-
cates that Y272 is also necessary for inhibition of PP1 by
phospho-DARPP-32. Interestingly, mutation of Y272 to phe-
nylalanine or alanine increased the ability of these mutant
proteins to dephosphorylate both a phospho-tyrosine substrate
and phospho-DARPP-32. These results provide additional sup-
port for the idea that phospho-T34 of DARPP-32 is situated
close to or in the active site of native PP1 in a manner that makes
it resistant to dephosphorylation. A268, P269, and Y272 are
conserved in PP2A; therefore, it is unlikely that these specific
amino acids mediate the PP1yphospho-inhibitor interaction.
Rather, the overall structure of the b12yb13 loop may establish
Fig. 5. Comparison of the regulation of PP1 and PP1yPP2A chimeras by
inhibitor-2. Phosphatase activity was measured in the presence of the indi-
cated concentrations of inhibitor-2. (A) Inhibition of wild-type PP1 and C-
terminal domain mutants derived from PP1 as indicated. (B) Inhibition of
PP1yPP2A chimera and mutants derived from the chimera as indicated. Phos-
phatase activity was measured as described in the Fig. 1 legend.
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the correct conformation of phospho-T34 of DARPP-32 (or
phospho-T35 of inhibitor-1) at or near the active site of PP1.
Results obtained from studies of the PP1yPP2A chimera, as
well as other previous structural studies (14, 20, 22, 30), indicate
that PP1-specific residues (C-terminal to C273) are likely to be
responsible for the binding of inhibitors and targeting subunits
to PP1 and subsequent regulation of enzyme activity. The
sequences GEFD (residues 274–277), MC (residues 290–291),
and QILK (residues 294–297) are unique to PP1 and may play
important roles in these interactions. The present study indicates
that M290 and C291 are the key residues involved in the
regulation of PP1 by thiophospho-DARPP-32. M290yC291 are
located at the beginning of the b14 strand of PP1 and, together
with L243, F257, and F293, help form the hydrophobic channel
that interacts with the docking motif of the GM peptide
(RRVSFA, residues 649-699) (14). Specifically, C291 makes
hydrophobic interactions with V669 and F689, hydrophilic inter-
actions with S679 and A699, and M291 makes a hydrophobic
interaction with A699. Thus, a specific contribution of M290 and
C291 to the binding of the docking motif of DARPP-32 would
have been predicted. However, assuming that F11 of DARPP-32
interacts with the hydrophobic channel of PP1 in the same way
as F68 of the GM peptide, continued contributions from L243,
F257, and F293 would have been expected. Given the size of the
effect of this limited substitution of M290 and C291 on inhibition
by thiophospho-DARPP-32, it is possible that subtle differences
might exist in the binding of the docking motif of the phospho-
inhibitors and the GM peptide. Finally, the lack of effect of
mutation of the GEFD and QILK residues on inhibition by
thiophospho-DARPP-32 may provide information about the
potential interaction(s) that the remainder of the inhibitory
domain of DARPP-32 makes with PP1.
In contrast to the results obtained with thiophospho-DARPP-
32, mutation of each of the three sets of PP1-specific residues
influenced inhibition by inhibitor-2 to a similar extent, and the
reverse mutations in the PP1yPP2A chimera had little effect.
Although inhibitor-2 lacks a canonical PP1-docking motif, re-
sults from the present study, as well as previous studies (5, 13),
showed that a peptide containing the PP1-docking motif [e.g.,
the PNUTS (392–408) peptide in this study] antagonized the
ability of inhibitor-2 to inhibit PP1. These effects may be indirect
and reflect an effect on the association of the unique N-terminal
region of inhibitor-2 with a region of PP1 adjacent to the
hydrophobic channel (18). Alternatively, inhibitor-2 may interact
in an extended fashion with each of the three PP1-specific
sequences, and mutation of any single region in the PP1yPP2A
chimera may be insufficient to restore regulation of PP1 by
inhibitor-2. In either case, these results further support the idea
that the interaction of inhibitor-2 with PP1 is distinct from that
of phospho-DARPP-32. These results also reinforce the idea
that differences exist in the interaction of the hydrophobic
channel with the various PP1-regulatory proteins, and that the
mutant PP1 proteins analyzed in this study might be useful tools
in physiological studies of PP1 function.
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